Review on uremic toxins:: Classification, concentration, and interindividual variability

被引:1340
作者
Vanholder, R
De Smet, R
Glorieux, G
Argilés, A
Baurmeister, U
Brunet, P
Clark, W
Cohen, G
De Deyn, PP
Deppisch, R
Descamps-Latscha, B
Henle, T
Jörres, A
Lemke, HD
Massy, ZA
Passlick-Deetjen, J
Rodriguez, M
Stegmayr, B
Stenvinkel, P
Tetta, C
Wanner, C
Zidek, W
机构
[1] State Univ Ghent Hosp, Dept Internal Med, Nephrol Sect, B-9000 Ghent, Belgium
[2] Inst Human Genet, Montpellier, France
[3] MAT Adsorpt Technol, Obernburg, Germany
[4] Ste Marguerite Hosp, Marseille, France
[5] Baxter Healthcare Corp, Lessines, Belgium
[6] Univ Vienna, Dept Med, Div Nephrol, Vienna, Austria
[7] Univ Antwerp, Lab Neurochem & Behav, Middelheim Hosp, Dept Neurol, B-2020 Antwerp, Belgium
[8] Gambro Corp Res, Hechingen, Germany
[9] Hop Necker Enfants Malad, INSERM, U507, Paris, France
[10] Tech Univ Dresden, Inst Food Chem, D-8027 Dresden, Germany
[11] Humboldt Univ, Fac Med, Campus Virchow Klinikum, UK Charite, Berlin, Germany
[12] Membrana GmbH, Obernburg, Germany
[13] Hop Necker Enfants Malad, Div Nephrol, CH Beauvais, Paris, France
[14] Hop Necker Enfants Malad, INSERM, U507, Paris, France
[15] Fresenius Med Care, Bad Homburg, Germany
[16] Univ Hosp Reina Sofia, Res Inst, Cordoba, Spain
[17] Norrlands Univ Hosp, Med Clin, Umea, Sweden
[18] Univ Hosp, Dept Nephrol, Huddinge, Sweden
[19] Univ Hosp, Div Nephrol, Wurzburg, Germany
[20] Univ Hosp Benjamin Franklin, Berlin, Germany
关键词
uremic toxins; uremic toxicity; renal failure; concentrations; retention;
D O I
10.1046/j.1523-1755.2003.00924.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The choice of the correct concentration of potential uremic toxins for in vitro, ex vivo, and in vivo experiments remains a major area of concern; errors at this level might result in incorrect decisions regarding therpeutic correction of uremia and related clinical complications. Methods. An encyclopedic list of uremic retention solutes was composed, containing their mean normal concentration (C-N), their highest mean/median uremic concentration (C-U), their highest concentration ever reported in uremia (C-MAX), and their molecular weight. A literature search of 857 publications on uremic toxicity resulted in the selection of data reported in 55 publications on 90 compounds, published between 1968 and 2002. Results. For all compounds, C-U and/or C-MAX exceeded C-N. Molecular weight was lower than 500 D for 68 compounds; of the remaining 22 middle molecules, 12 exceeded 12,000 D. C-U ranged from 32.0 ng/L (methionine-enkephalin) up to 2.3 g/L (urea). C-U in the ng/L range was found especially for the middle molecules (10/22; 45.5%), compared with 2/68 (2.9%) for a molecular weight <500 D (P < 0.002). Twenty-five solutes (27.8%) were protein bound. Most of them had a molecular weight <500 D except for leptin and retinol-binding protein. The ratio C-U/C-N, an index of the concentration range over which toxicity is exerted, exceeded 15 in the case of 20 compounds. The highest values were registered for several guanidines, protein-bound compounds, and middle molecules, to a large extent compounds with known toxicity. A ratio of C-MAX /C-U <4, pointing to a Gaussian distribution, was found for the majority of the compounds (74/90; 82%). For some compounds, however, this ratio largely exceeded 4 [e.g., for leptin (6.81) or indole-3-acetic acid (10.37)], pointing to other influencing factors than renal function, such as gender, genetic predisposition, proteolytic breakdown, posttranslation modification, general condition, or nutritional status. Conclusion. Concentrations of retention solutes in uremia vary over a broad range, from nanograms per liter to grams per liter. Low concentrations are found especially for the middle molecules. A substantial number of molecules are protein bound and/or middle molecules, and many of these exert toxicity and are characterized by a high range of toxic over normal concentration (C-U/C-N ratio). Hence, uremic retention is a complex problem that concerns many more solutes than the current markers of urea and creatinine alone. This list provides a basis for systematic analytic approaches to map the relative importance of the enlisted families of toxins.
引用
收藏
页码:1934 / 1943
页数:10
相关论文
共 88 条
[1]   Anorexigen (TNF-α, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients:: their relationship with nutritional parameters [J].
Aguilera, A ;
Codoceo, R ;
Selgas, R ;
Garcia, P ;
Picornell, M ;
Diaz, C ;
Sanchez, C ;
Bajo, MA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (06) :1476-1483
[2]   THE MIDDLE MOLECULE HYPOTHESIS IN PERSPECTIVE [J].
BABB, AL ;
AHMAD, S ;
BERGSTROM, J ;
SCRIBNER, BH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1981, 1 (01) :46-50
[3]   Homocysteine and lipid peroxidation in haemodialysis:: role of folinic acid and vitamin E [J].
Bayés, B ;
Pastor, MC ;
Bonal, J ;
Juncà, J ;
Romero, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (11) :2172-2175
[4]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[5]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[6]   Relationship of dialysis membrane and cause-specific mortality [J].
Bloembergen, WE ;
Hakim, RM ;
Stannard, DC ;
Held, PJ ;
Wolfe, RA ;
Agodoa, LYC ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (01) :1-10
[7]   HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[8]   The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass [J].
Brulez, HFH ;
van Guldener, C ;
Donker, AJM ;
ter Wee, PM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (01) :154-159
[9]   Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients [J].
Cohen, G ;
Rudnicki, M ;
Schmaldienst, S ;
Hörl, WH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (05) :879-883
[10]   High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients [J].
Coyne, DW ;
Dagogo-Jack, S ;
Klein, S ;
Merabet, E ;
Audrain, J ;
Landt, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (06) :1031-1035